Standard Induction Therapy for Acute Myeloid Leukemia
For younger fit patients (<60 years), standard induction therapy is cytarabine 100-200 mg/m² continuous infusion for 7 days combined with either daunorubicin 60-90 mg/m² or idarubicin 12 mg/m² for 3 days (the "7+3" regimen), with specific targeted agents added based on molecular features. 1
Treatment Algorithm for Fit Younger Patients (<60 years)
Start with the 7+3 backbone and modify based on molecular/cytogenetic features:
FLT3-mutated AML with intermediate-risk cytogenetics: Add midostaurin to cytarabine (200 mg/m²) + daunorubicin (60 mg/m²) 1
CD33-positive AML with favorable or intermediate-risk cytogenetics: Add gemtuzumab ozogamicin to cytarabine + daunorubicin 1
Therapy-related AML (t-AML), antecedent hematologic disorder, or AML with myelodysplasia-related changes (AML-MRC): CPX-351 [daunorubicin 44 mg/m² + cytarabine 100 mg/m² as 90-minute infusion on days 1,3,5] is the preferred option (category 1 recommendation) 1
Favorable, intermediate, or poor-risk cytogenetics without the above features: Standard 7+3 remains appropriate 1
Treatment Modifications for Older/Unfit Patients (≥60 years)
The critical decision point is determining fitness for intensive chemotherapy, which should be based on performance status, comorbidities, and patient goals—not age alone. 2
For Patients Fit for Intensive Therapy
Standard 7+3 regimen remains an option, with the same molecular-targeted additions as younger patients 1. However, for patients aged >75 years, eligibility for intensive chemotherapy should be evaluated extremely carefully 2, as venetoclax-based regimens now offer comparable or superior outcomes with better tolerability.
For Patients Unfit for Intensive Therapy or Age >75 Years
Venetoclax combined with a hypomethylating agent (azacitidine or decitabine) or low-dose cytarabine is the preferred approach 1, 3. This represents a paradigm shift in AML treatment for this population.
Specific regimens in order of preference:
- Venetoclax + azacitidine or decitabine (preferred for most patients) 1, 3
- Venetoclax + low-dose cytarabine 1
- Glasdegib + low-dose cytarabine 1
- Hypomethylating agent monotherapy (azacitidine or decitabine, 5 or 10-day regimens) 1
- Gemtuzumab ozogamicin monotherapy 1
- Low-dose cytarabine alone 1
Molecular-Targeted Modifications for Unfit Patients
IDH1-mutated AML in patients ≥75 years or with prohibitive comorbidities: Ivosidenib 500 mg daily is FDA-approved as first-line therapy, with CR/CRh rates of 41% 1. Alternatively, venetoclax/HMA combinations show >70% remission rates in IDH1/2-mutated AML 1.
IDH2-mutated AML: Enasidenib is an option, though venetoclax/HMA may be preferred given higher response rates 1.
FLT3-mutated AML in unfit patients: Azacitidine + gilteritinib showed 67% CR/CRi rates in a small trial 1. The 2025 ASH guidelines recommend incorporating FLT3 inhibitors even in non-intensive approaches 3.
Critical Performance Status Considerations
Performance status is more predictive than age alone 2:
- ECOG 0-2: Consider intensive therapy if age <75 years and no prohibitive comorbidities
- ECOG >2: Geriatric assessment recommended to inform treatment intensity decision 2
- ECOG >3: Decision between active treatment and supportive care should be individualized, but venetoclax-based regimens remain feasible 2
Key Pitfalls to Avoid
Do not use age as the sole criterion for treatment selection. A 75-year-old with ECOG 0 and no comorbidities may tolerate intensive therapy, while a 65-year-old with ECOG 3 and multiple comorbidities will not 2.
For unfavorable-risk cytogenetics (excluding AML-MRC), venetoclax + azacitidine/decitabine/low-dose cytarabine is now a recommended option even for fit patients, representing a shift away from mandatory intensive chemotherapy for all fit patients 1.
Differentiation syndrome risk: Both enasidenib and ivosidenib can cause differentiation syndrome and hyperleukocytosis—manage proactively with corticosteroids and hydroxyurea 1.
The EORTC-GIMEMA 1301 trial demonstrated comparable survival and improved quality of life with 10-day decitabine versus intensive chemotherapy in fit patients >60 years 2, supporting less-intensive approaches even in traditionally "fit" older patients, particularly when venetoclax is added.